Sensorium is a clinical-stage biotech developing first-in-class CNS therapies, guided by human biology and nature’s neuroactive patterns, to relieve suffering and restore wellbeing.
Our programs include SENS-01 for anxiety, SENS-03 for epilepsy, and SENS-08 for cognitive dysfunction associated with neurodegenerative disease. SensAI™, our platform integrating expert-curated natural product data, proprietary AI tools, and chemical analysis, identifies patterns across 50+ million data relationships to guide new drug discovery.
Lead program in social anxiety disorder in Phase 1 trial
We discern patterns across eons of chemical evolution and millennia of knowledge with a mission to transform mental health and CNS treatment.
the latest
Follow our progress as we propel and expand treatments for CNS disorders in promising new directions.
innovative by nature
Our pipeline addresses CNS disorders where existing treatments fall short. Each program starts from compounds humans have found effective, understood through modern pharmacology and neuroscience.
SENS-01 is a novel serotonin modulator with a mechanism that is differentiated from conventional SSRIs and the potential for rapid onset and improved tolerability. Initial development is focused on anxiety, with potential applicability across multiple CNS disorders. The current Phase 1 study is evaluating safety, pharmacokinetics, and target engagement biomarkers.
The SENS-03 program is advancing a proprietary small molecule series targeting mechanisms distinct from currently approved antiseizure medications. Preclinical studies have shown antiseizure activities in multiple models. A development candidate will be nominated in 2H 2026.
SENS-08 is a discovery program advancing proprietary small molecules for cognitive dysfunction associated with neurodegenerative disease, an area with significant unmet medical need and few pharmacologic treatment options. The program originates from a natural product with a long-documented history of human use. SENS-08 is in early preclinical development and supported by a $3.5M NIH award.
Discovery engine
SensAI integrates natural compounds, human experience, pharmacology, and neuroscience across 50M+ relationships to identify therapeutic patterns screening-based approaches cannot systematically find.
Molecular structures, properties, and relationships across natural compound libraries (>700K natural products)
Documented traditional uses spanning cultures and millennia—expert-curated evidence of what compounds humans found effective and for what conditions (>100K plants, >250K references)
Mechanisms of action, receptor binding, metabolic pathways, and physiological effects (>1M bioassays)
Brain chemistry, neural circuits, disease mechanisms, and therapeutic targets in CNS disorders
Anxiety
SENS–01
Phase 1
Drug-resistant epilepsy
SENS–03
Lead candidate
Built for this moment
We’re pattern seekers who decode eons of evolution and millennia of human experience, impatient with the status quo in CNS therapies. With tools we built, our leaders and scientists systematically explore nature’s therapeutic motifs to retrieve more people from suffering.
For millennia, humans discovered which natural compounds heal the mind. Sensorium systematically explores these insights alongside chemistry and neuroscience to recover therapeutic opportunities modern discovery abandoned.
We’re translating patterns into precision therapeutics that may enrich human wellbeing and retrieve people from suffering.
Let’s talk
Nearly 85% of approved CNS drugs are derived from nature.
Our SensAI platform integrates 50M+ relationships across natural compounds, human experience, pharmacology, and neuroscience.
We have developed three programs in three years, each with novel MOAs.
SENS–01, our first-in-class precision anxiety therapy, is in the clinic. Novel serotonin modulator for social anxiety; rapid onset, reduced side effects; multi-indication potential (GAD, OCD, PTSD)
SENS–03 is our program for drug-resistant epilepsy with the potential to also reduce co-occurring anxiety; development candidate selection 2H 2026
SENS–08 is our NIH-funded preclinical program for Alzheimer’s-related cognitive impairment
Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class compound under investigation for the treatment of anxiety disorders—and built a robust IP estate extending into the 2040s.
© 2026 Sensorium Therapeutics.
All rights reserved.
FCOI policy
Privacy policy